Skip Navigation LinksHome > May 2014 - Volume 36 - Issue 4 > Chediak-Higashi Syndrome: Novel Mutation of the CHS1/LYST G...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000025
Online Articles: Clinical and Laboratory Observations

Chediak-Higashi Syndrome: Novel Mutation of the CHS1/LYST Gene in 3 Omani Patients

Al-Tamemi, Salem MD, FRCPC*; Al-Zadjali, Shoaib PhD; Al-Ghafri, Fahad MD; Dennison, David MBBS, MD

Collapse Box


Background: Chediak-Higashi syndrome (CHS) is a rare, autosomal, recessive lysosomal disorder with hematological and immunologic abnormalities; however, stem-cell transplantation from a matched or related donor may be curative. Many mutations of the CHS1/LYST gene have been reported to date. We report a novel nonsense mutation of the CHS1/LYST gene in 3 Omani patients.

Methods and Results: Three patients from 2 different families presented with clinical and laboratory features of CHS and a history of death of a previous sibling because of a severe illness, suggestive of the accelerated phase of CHS. Giant granules were present in the myeloid cell lines. Before the stem-cell transplant, the first patient underwent gene sequencing of all exons of the lysosome trafficking regulator (CHS1/LYST) gene and revealed a nonsense mutation in exon 5 (c.925C>T, p.R309X). Subsequently, upon presentation, the second and third patients’ direct gene sequencing of exon 5 revealed the same mutation.

Conclusions: We report a nonsense mutation in exon 5 (c.925C>T, p.R309X). This supports the allelic heterogeneity of CHS and is in line with most reported mutation types that lead to a truncated protein. Identification of the mutation type will facilitate timely diagnosis, management, and family counseling for those with affected children in Oman.

© 2014 by Lippincott Williams & Wilkins.


Article Tools


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.